Intuitive Surgical is expected to report Q1 2026 revenue of $2.62 billion and earnings per share of $1.63, as the stock trades at $469.21 compared to an average analyst price target of $608.24.
The primary focus for this report is the worldwide da Vinci procedure growth, which serves as a leading indicator for the company's recurring revenue streams.
Investors are closely monitoring the commercial rollout of the Da Vinci 5 platform following a year where system placements reached record levels. Concerns regarding tariff exposure and potential manufacturing headwinds in Mexico and China will also be scrutinized for any shifts in 2026 guidance.